Compare PAVS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVS | TLSA |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 145.1M |
| IPO Year | 2018 | 2017 |
| Metric | PAVS | TLSA |
|---|---|---|
| Price | $4.03 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.97 |
| AVG Volume (30 Days) | 11.2K | ★ 545.0K |
| Earning Date | 08-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $541.46 | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.76 |
| 52 Week High | $26.69 | $2.33 |
| Indicator | PAVS | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 59.09 |
| Support Level | $3.86 | $0.90 |
| Resistance Level | $5.55 | $1.20 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 10.00 | 94.69 |
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.